Introduction
Primary IgA nephropathy (IgAN)' has been found to be the most common form of primary glomerulonephritis in all countries where adequate epidemiological data have been acquired (1) . The disease is characterized by mesangial deposits ofIgA, and there is now widespread agreement that the mesangial IgA contains almost exclusively the subclass IgA 1 (2) (3) (4) (5) (6) (7) (8) . Patients with IgAN have increased IgA plasma levels (4, 9-1 1). This increase in IgA was recently found to be due to elevated levels of IgA 1 (i2-14). Circulating immune complexes in IgAN also contain predominantly the subclass IgAl (7, 15, 16) . A shift in the IgA subclass distribution toward IgAI has re-cently been found in the Ig produced by peripheral blood lymphocytes (14), and in the plasma cells in the bone marrow (17) and tonsils (18) of patients with IgAN. From these data it becomes evident that the biological abnormalities in the IgA system in patients with IgAN are predominantly or exclusively restricted to the subclass IgA 1. The pathogenetic significance of polymeric IgA in IgAN is a subject ofcontroversy. The mesangial deposits were found to contain polymeric IgA by some investigators (7, (19) (20) (21) , but not by others (2, 5, 6, 8) . In the plasma, polymeric IgA was found to be elevated in two studies (7, 22) , but no absolute (I 1, 23, 24) or relative (6, 12, 13, 25, 26) increase was found by others. These conflicting results can be partially explained by the fact that elevated serum levels of polymeric IgA are found predominantly during attacks of macroscopic hematuria (26) . In recent studies predominantly monomeric IgA was found in the circulating immune complexes (6, 16, 27) .
The elevated serum levels of IgA presumably are the result of increased synthesis. A few studies have addressed the question of whether patients with IgAN have a higher than normal serum IgA immune response upon immunization. Parenteral immunization with inactivated influenza virus (28) and mumps virus (29) may lead to higher serum IgA responses in patients with IgAN. However, in the study with influenza virus no significant difference between patients and controls was reported (28) . In the study with mumps virus the titers ofIgAN patients were not significantly different from those in healthy controls, but they were significantly higher than the titers in patients with IgM glomerulonephritis (29) . Oral immunization with polio vaccine resulted in significantly higher antigen-specific serum IgA responses in patients than in controls (30) . However, none of these studies measured the subclass distribution and molecular size of the antigen-specific IgA ELISA. Isotype-and subclass-specific serum antibody responses against A/Singapore/6/86 influenza virus were measured by ELISA. The antigen was prepared by growing A/Singapore/6/86 in the allantoic cavity of embryonated eggs. The allantoic fluid was harvested, diluted 1:4 in PBS, and the virus inactivated with 0.1 mg/ml Merthiolate. The fluid was clarified by centrifugation at 2,000 g for 10 min at 4°C. The allantoic fluid was further diluted 1:10 with Veronal-buffered saline (VBS), pH 7.4, containing 10% sucrose. The virus was sedimented by ultracentrifugation at 100,000 g for 90 min at 20°C. The pellet was resuspended in VBS-sucrose using a syringe and 19-gauge needle. The ultracentrifugation step was repeated and the purified virus was stored in VBS-sucrose in small aliquots at -70°C. Flat-bottomed polystyrene microtiter plates (Titertek; Flow Laboratories, Zwanenburg, The Netherlands) were coated with an optimal dilution of the virus in carbonate buffer, pH 9.6, for 2 h at 37°C. In the ELISA measuring the IgA subclasses, nonspecific binding sites were then blocked by incubation with PBS containing 0.05% Tween 20 and 5% heat-inactivated newborn calf serum (NBCS) for 2 h at 37°C. The plates were washed with PBS-Tween three times. Samples were diluted in PBS-Tween containing 1% NBCS and incubated in the virus-coated wells overnight at room temperature. After three washes with PBSTween, bound antibodies were detected with isotype-specific murine MAbs applied for 2 h at 37°C. For the detection of IgM we used the biotin-conjugated MAb HB57, and for IgG we used the biotin-conjugated MAb HB43 (American Type Culture Collection, Rockville, MD). IgA was detected with a biotin conjugate of the MAb NI 69 (Nordic Immunological Laboratories, Tilburg, The Netherlands). IgA subclasses were detected with the MAbs NI 69-11 (anti-IgA I) and NI 512 (anti-IgA2) (Nordic Immunological Laboratories), followed by biotin-coupled goat anti-mouse IgG. After three washes with PBSTween, streptavidine conjugated to horseradish peroxidase (Zymed, Sanbio B.V., Uden, The Netherlands) in PBS-Tween-NBCS was applied to the wells for I h at 37°C. The wells were washed three times with PBS-Tween, and substrate (o-phenylenediamine; Sigma Chemical Co., St. Louis, MO) conversion was read at 492 nm according to conventional methods.
All antiinfluenza titers are expressed in arbitrary units per milliliter, relative to a standard serum yielding high OD values in the ELISA for a certain isotype. A different standard serum was chosen for each isotype, and this standard serum was used in a dilution series on each ELISA plate. The standard sera yielded increasing OD values in a dose-dependent fashion to values of at least 1.000, and usually > 2.000. For the isotypes IgM, IgG, and IgA, the titer assigned to the standard serum was 1,000 U/ml. The two IgA subclasses were measured relative to a single strongly positive serum with arbitrary titers of 8,000 U/ml of IgAl and 2,000 U/ml of IgA2. Sample titers were calculated from the standard curves thus obtained. Blank values, obtained on each plate using PBS-Tween-NBCS, were usually < 0.050, and were subtracted from the OD values of standards and samples. Calculations were made at sample dilutions yielding an OD in the lower steep part of the curve.
To exclude an artifact in the IgA I antiinfluenza ELISA due to the possible presence of IgA 1 rheumatoid factor in the sera, as has been reported by other investigators (16), we performed a control experiment using absorption to immobilized IgG. The sera obtained on days 0 and 14 were diluted 1:5 in PBS-Tween-NBCS, and a 500-pd sample was incubated for 1 h at room temperature with 1 ml (packed volume) of an immunoabsorbent of human IgG coupled to Biogel A5 (Bio-Rad Laboratories B.V., Utrecht, The Netherlands). For comparison, the diluted sera were incubated in a parallel fashion with a control immunoabsorbent. After separation of the absorbed samples from the immunoabsorbent by centrifugation the samples were tested for IgA 1 antiinfluenza in the ELISA mentioned above. Separate experiments demonstrated that the absorption technique used was capable of consistently removing > 95% of the IgAI rheumatoid factor from two strongly positive sera from patients with rheumatoid arthritis. The titer of IgA 1 antiinfluenza antibodies was not reduced in either the patients or the controls when comparing the IgG absorption with the control absorption. This demonstrates that the presence of IgAl rheumatoid factor does not influence the results in the IgA 1 antiinfluenza ELISA in any significant way.
HPLC. The size distribution ofthe influenza-specific IgA was studied using molecular sieving HPLC. The sera obtained on days 14 and 28 were diluted 1:20 with 0.1 M phosphate buffer with 0.1 M NaCl (pH 6.8) and passed through a 0.22-Mm filter (Millipore/Continental Water Systems, Bedford, MA). 200 ul ofeach sample was then injected onto a TSK G3000 SW column connected via a guard column to an HPLC pump (LKB, Bromma, Sweden). The column was equilibrated and run in 0.1 M phosphate buffer with 0.1 M NaCl, pH 6.8, at a flow rate of0.3 ml/min. 1-min fractions were collected and assayed for total IgA content using the ELISA previously described (17). Based on the IgA elution profile thus obtained, fractions were pooled to form polymeric and monomeric pools for each HPLC run. The volume for each pool was determined by multiplying the number of fractions with the mean fraction volume measured in each HPLC run. In each pool the titer of influenza-specific IgA and IgAl was determined with the ELISA described above. The amount ofantigen-specific IgA2 in the HPLC pools proved to be too low for detection by the ELISA. The total number of polymeric and monomeric units in each sample was determined by multiplying the titer with the pool volume. The percentage of polymeric IgA and IgA I was calculated by dividing the polymeric units by the sum of polymeric and monomeric units. Two sera from the patient group and one control serum were not available for study. Consequently, the analysis was performed on 16 patients and 21 controls. Data analysis. All data are expressed as arithmetic means±SEM.
The data were analyzed by two-way analysis of variance to study the effect ofboth group (patient versus control) and time after vaccination. For the serum titers and the units of influenza-specific antibody in the polymeric and monomeric pools, this analysis of variance was performed on their logarithmic values to normalize the data distribution. The isotype ratios in individual sera and the percentage ofpolymers in the HPLC study were calculated from the nontransformed data. Statistical analysis was performed with the Statgraphics software package (STSC Inc., Rockville, MD).
Results
Isotype-specific serum immune response. The logarithmically transformed titers of IgM, IgG, IgA, IgAI, and IgA2 antiinfluenza antibodies are plotted against time after vaccination in Figs. 1 and 2 . Analysis of variance revealed a significant (P < 0.0001) increase in the IgM antiinfluenza titer after vaccination. The IgM response, however, did not differ between patients and controls (P = 0.36). IgG antiinfluenza titers also increased significantly after vaccination (P < 0.0001), with no significant difference between patients and controls (P = 0.31).
A significant (P < 0.0001) increase was also found for the IgA antiinfluenza titers in time, and although patients had a higher immune response, the difference with healthy controls was not statistically significant at the 0.05 level (P = 0.058). The IgAl antiinfluenza titers also increased significantly after immunization (P = 0.001). The IgA 1 immune response was markedly higher in patients than in healthy controls (P < 0.0001). The peak ofthe IgA 1 antiinfluenza also appeared to occur earlier in patients (day 7) than in controls (day 14). For the subclass IgA2 a significant increase in the titers after immunization was also found (P < 0.0001), with no significant difference between the two groups (P = 0.44).
Isotype ratios of the immune response. The ratio of the titers of IgA and IgG antiinfluenza antibodies was calculated for each serum sample. Two-way analysis of variance demonstrated a significantly higher (P = 0.01) IgA/IgG ratio in the patients than in the controls. The influenza-specific IgA/IgG ratio did not change significantly over the weeks after vaccination (P = 0.49). The ratio of the IgA titer over the sum of the 4 . titers of the isotypes IgA, IgG, and IgM was also significantly higher in patients than controls (P = 0.039). This ratio did not vary significantly over time (P = 0.26).
The ratio ofthe IgA 1 antiinfluenza titer over the sum ofthe IgA 1 and IgA2 titers was also calculated for each serum sample. This ratio was significantly higher (P < 0.0001) in patients than in controls. The IgA subclass ratio also changed significantly over time after vaccination (P < 0.0001). This was due to the fact that the mean IgAl response reached its peak value at an earlier time (day 7) than the mean IgA2 response (day 14), especially in the patient group.
HPLC size analysis of the influenza-specific IgA. Data from the HPLC study of the sera obtained on days 14 and 28 after vaccination are summarized in Table I . Polymeric IgA antiinfluenza was not found to be significantly different between patients and controls (P = 0.94) in a two-way analysis of variance. This was also the case for polymeric IgA 1 antiinfluenza antibodies (P = 0.19). Monomeric IgA antiinfluenza was not higher in patients than in controls (P = 0.28). However, the influenza-specific monomeric IgA 1 was significantly higher in patients with IgAN than in healthy controls (P = 0.035). With respect to the effects of time after immunization, the analysis of variance showed the polymeric IgA antiinfluenza to be significantly higher on day 14 than 28 (P = 0.009). The differences between days 14 and 28 were not significant for polymeric IgA 1 (P = 0.21), monomeric IgA (P = 0.13), or monomeric IgA 1 (P = 0.69).
The relative amount of polymeric antigen-specific IgA or IgA 1 was expressed as the percentage of total antigen-specific IgA or IgA 1 in each serum sample. Between the two groups these percentages ofpolymeric IgA and IgAl antiinfluenza did not differ (P = 0.09 and 0.30, respectively). The percentage of polymeric IgA and IgA 1 antibodies appeared to decrease over time after immunization (P = 0.06 for IgA and 0.01 for IgA 1). (12, 14) , in the bone marrow (17), in the tonsils (18) , and in cultures of peripheral blood lymphocytes (14) from patients with IgAN. The present study shows that this subclass shift is also demonstrable in an antigen-specific study. This is an important observation, since it sheds light on the possible mechanism of the selective IgA The considerable contribution of polymeric forms of IgA and IgAl to the total immune response in these isotypes noted in this study is not surprising in view ofthe recent literature on this subject. The antigen-specific IgA induced in the serum was found to be polymeric to a large extent, not only after mucosal antigen presentation (31, 33) , but also after systemic immunization or infection (34, (41) (42) (43) . In some investigations it was found that polymeric forms of IgA occurred especially in the early immune response, and that the percentage of polymeric antigen-specific IgA decreased at longer time intervals after the presentation of antigen (41, 42) . A decrease in the percentage of polymeric IgA antiinfluenza in the course of time was also noted in the present study, and this decrease appeared to be more marked in the patient group.
In summary, the data indicate that patients with IgAN have a higher than normal immune response to parenterally administered inactivated influenza vaccine, limited to the IgAl isotype. On the basis of previous studies (28) (29) (30) , this hyperresponsiveness does not appear to be limited to influenza, but applies to various viral antigens. Therefore, the hyperresponsiveness seems to be polyclonal in nature. Further studies should elucidate whether this hyperresponsiveness is due to a regulatory defect in these patients.
